{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:55:12Z","timestamp":1788998112721,"version":"build-2803163510"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.intimp.2026.116747","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:05Z","timestamp":1777591025000},"page":"116747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements"],"prefix":"10.1016","volume":"181","author":[{"given":"Abhijeet","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Wankhade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Podobnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Eifler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.intimp.2026.116747_bb0005","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0010","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.intimp.2026.116747_bb0015","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tibtech.2004.03.006","article-title":"A revival of bispecific antibodies","volume":"22","author":"Kufer","year":"2004","journal-title":"Trends Biotechnol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0020","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116747_bb0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"issue":"11","key":"10.1016\/j.intimp.2026.116747_bb0030","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","article-title":"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin","volume":"25","author":"Wu","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.116747_bb0035","unstructured":"Cogan DG, et al. Bispecific antibody for the treatment of ophthalmologic diseases: clinical potential and challenges Eye (Lond.) 2022;36(2):210\u2013216. doi:https:\/\/doi.org\/10.1038\/s41433-021-01629-7."},{"issue":"10","key":"10.1016\/j.intimp.2026.116747_bb0040","first-page":"885","article-title":"Harnessing bispecific antibody for combating antimicrobial resistance","volume":"29","author":"Lu","year":"2021","journal-title":"Trends Microbiol."},{"issue":"2 Pt A","key":"10.1016\/j.intimp.2026.116747_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibody","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself."},{"issue":"14","key":"10.1016\/j.intimp.2026.116747_bb0055","first-page":"7437","article-title":"Therapeutic potential of bispecific antibody in the treatment of HIV-1 infection","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116747_bb0060","article-title":"Subcutaneous delivery of bispecific antibody: scientific rationale and current developments","volume":"157","author":"Tzogani","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"14","key":"10.1016\/j.intimp.2026.116747_bb0065","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116747_bb0070","unstructured":"Regeneron Pharmaceuticals. (2024, April). Regeneron CD20xCD3 bispecific REGN1979 shows positive results in relapsed\/refractory NHL. Retrieved from https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-cd20xcd3-bispecific-regn1979-shows-positive-results."},{"key":"10.1016\/j.intimp.2026.116747_bb0075","unstructured":"Reuters. (2024, April 21). Gilead Says Trodelvy-Keytruda Combo Effective in Aggressive Breast cancer Type. Retrieved from https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/gilead-says-trodelvy-keytruda-combo-effective-aggressive-breast-cancer-type-2025-04-21\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0080","first-page":"1230","article-title":"LAG-3\/PD-1 bispecific antibody in patients with advanced solid tumors: a phase 1 trial","volume":"27","author":"Marabelle","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.116747_bb0085","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1002\/art.40319","article-title":"ABT-122, a bispecific dual variable domain immunoglobulin targeting tumor necrosis factor and interleukin-17A, in patients with rheumatoid arthritis with an inadequate response to methotrexate: a randomized, double-blind study","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.intimp.2026.116747_bb0090","unstructured":"IUPHAR\/BPS Guide to PHARMACOLOGY. (n.d.). COVA322. Retrieved from https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=10469&tab=clinical."},{"issue":"24","key":"10.1016\/j.intimp.2026.116747_bb0095","doi-asserted-by":"crossref","first-page":"9326","DOI":"10.1074\/jbc.M117.818559","article-title":"A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases","volume":"293","author":"Lyman","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0100","first-page":"365","article-title":"The immunologic role of IL-17 and IL-23 in psoriasis and their implications for targeted biologic treatments","volume":"79","author":"Blauvelt","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0105","first-page":"710","article-title":"The role of CD40 ligand in systemic lupus erythematosus","volume":"50","author":"Koshy","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2026.116747_bb0110","unstructured":"GSK. (2021). Vir Biotechnology and GSK announce VIR-7831 reduces hospitalization and risk of death in early treatment of adults with COVID-19. Retrieved from https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0115","article-title":"Bispecific antibody targeting HIV gp120 and gp41 show potent neutralizing activity","volume":"12","author":"Adams","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116747_bb0120","article-title":"Bispecific antibody targeting influenza virus: a new approach to overcome viral resistance","volume":"178","author":"Green","year":"2020","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116747_bb0125","article-title":"Overcoming antimicrobial resistance with bispecific antibody: current research and future directions","volume":"60","author":"Li","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2026.116747_bb0130","unstructured":"Barrons. (2024). Biogen's BIIB091: a LRRK2 inhibitor antibody for Parkinson's disease. Retrieved from https:\/\/www.barrons.com\/articles\/abbvie-alzheimer-roche-antibody-9999aefc."},{"key":"10.1016\/j.intimp.2026.116747_bb0135","article-title":"Amyloid-beta and inflammatory cytokine Bispecific antibody in Alzheimer\u2019s disease: emerging therapeutic strategies","volume":"195","author":"Xu","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0140","first-page":"333","article-title":"Alpha-synuclein and inflammatory cytokine bispecific antibody for Parkinson's disease treatment","volume":"15","author":"Wang","year":"2023","journal-title":"Neurodegener. Dis. Manage."},{"issue":"1","key":"10.1016\/j.intimp.2026.116747_bb0145","article-title":"EGFR\/PD-1 Bispecific antibody in glioblastoma: Targeting brain tumors with immune checkpoint blockade","volume":"12","author":"Zhang","year":"2023","journal-title":"OncoImmunology"},{"key":"10.1016\/j.intimp.2026.116747_bb0150","unstructured":"AstraZeneca. (2017). AstraZeneca and Pieris Pharmaceuticals collaborate to develop and commercialize anticalin-based inhaled treatments for respiratory diseases. Retrieved from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2017\/astrazeneca-and-pieris-pharmaceuticals-collaborate-to-develop-and-commercialise-anticalin-based-inhaled-treatments-for-respiratory-diseases-03052017.html."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0155","first-page":"1767","article-title":"PCSK9 inhibitors: targeting lipid accumulation and inflammatory pathways for atherosclerosis and cardiovascular disease","volume":"29","author":"Zhao","year":"2021","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2026.116747_bb0160","first-page":"689","article-title":"Bispecific antibody in cardiovascular and metabolic diseases: focus on VEGF\/VEGFR therapies for heart failure","volume":"19","author":"Coelho","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0165","first-page":"302","article-title":"Bispecific antibody targeting VEGF and Ang2: Emerging treatments for heart failure and vascular health","volume":"132","author":"Sahu","year":"2023","journal-title":"Circ. Res."},{"issue":"23","key":"10.1016\/j.intimp.2026.116747_bb0170","first-page":"2463","article-title":"Emicizumab: a bispecific antibody for hemophilia a treatment","volume":"130","author":"Tiede","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116747_bb0175","unstructured":"Cystic Fibrosis Foundation. (2023). CFTR Modulator therapies. Retrieved from https:\/\/www.cff.org\/managing-cf\/cftr-modulator-therapies."},{"issue":"5","key":"10.1016\/j.intimp.2026.116747_bb0180","first-page":"567","article-title":"Advances in bispecific antibody treatments for cystic fibrosis: targeting CFTR to enhance lung function","volume":"21","author":"Malec","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.intimp.2026.116747_bb0190","first-page":"46","article-title":"Development and clinical application of bispecific antibody: a focus on subcutaneous administration","volume":"109","author":"S\u00f6rgel","year":"2021","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0195","first-page":"287","article-title":"Bispecific antibody: advances in drug delivery technologies","volume":"399","author":"Zhang","year":"2018","journal-title":"Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116747_bb0200","unstructured":"Genmab & AbbVie. (2020). Genmab and AbbVie announce topline results for epcoritamab (DuoBody\u00ae-CD3xCD20) from Phase 1\/2 trial in patients with relapsed\/refractory large B-cell lymphoma. Genmab. Retrieved from https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-and-abbvie-announce-topline-results-epcoritamab-duob."},{"key":"10.1016\/j.intimp.2026.116747_bb0205","unstructured":"Halozyme Therapeutics. (n.d.). ENHANZE\u00ae drug delivery technology. Retrieved from https:\/\/halozyme.com\/drug-delivery-technologies\/enhanze\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0210","unstructured":"Roche. (2022). Roche's subcutaneous formulation of Tecentriq demonstrates faster administration and reduced burden for patients. Retrieved from https:\/\/www.roche.com\/media\/releases\/med-cor-2022-08-02."},{"key":"10.1016\/j.intimp.2026.116747_bb0215","unstructured":"Xeris Biopharma. (2022). Xeris Biopharma announces research collaboration and option agreement with Horizon Therapeutics to develop subcutaneous formulation of teprotumumab. Retrieved from https:\/\/xerispharma.com\/news-releases\/news-release-details\/xeris-biopharma-announces-research-collaboration-and-option."},{"key":"10.1016\/j.intimp.2026.116747_bb0220","unstructured":"Xencor. (n.d.). Xtend\u2122 Fc domains. Retrieved from https:\/\/xencor.com\/technology\/xtend-fc-domains\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0225","unstructured":"Alteogen. (2020). Alteogen presents the first-in-human data on ALT-P7, a HER2-targeting antibody-drug conjugate (ADC) at ASCO 2020. Retrieved from https:\/\/www.biospace.com\/alteogen-presents-the-first-in-human-data-on-alt-p7-a-her2-targeting-antibody-drug-conjugate-adc-at-asco-2020."},{"key":"10.1016\/j.intimp.2026.116747_bb0230","unstructured":"AstraZeneca. (2021). AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint. Retrieved from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/azd7442-prophylaxis-trial-met-primary-endpoint.html."},{"key":"10.1016\/j.intimp.2026.116747_bb0235","unstructured":"Aptevo Therapeutics. (2020). Aptevo Therapeutics provides update on ongoing APVO436 Phase 1\/1b clinical trial. Retrieved from https:\/\/aptevotherapeutics.gcs-web.com\/news-releases\/news-release-details\/aptevo-therapeutics-provides-update-ongoing-apvo436-phase-1-0."},{"key":"10.1016\/j.intimp.2026.116747_bb0240","unstructured":"Molecular Templates. (2022). Molecular templates, inc. - SEC.Gov. Retrieved from https:\/\/www.sec.gov\/Archives\/edgar\/data\/1183765\/000119312524199839\/d883792dars.pdf."},{"key":"10.1016\/j.intimp.2026.116747_bb0245","unstructured":"INmune Bio. (2024). INmune bio inc. completes enrollment for phase 2 trial in early alzheimers disease. Retrieved from https:\/\/www.inmunebio.com\/index.php\/newsroom\/2024news\/muneioncompletesnrollmentforhase2rialina20240930050502."},{"key":"10.1016\/j.intimp.2026.116747_bb0250","unstructured":"Zymeworks. (2023). ZW171, a T cell-engaging, bispecific antibody for the treatment of MSLN-expressing tumors. Retrieved from https:\/\/www.zymeworks.com\/wp-content\/uploads\/2023\/04\/ZW171-Poster_AACR-2023.pdf."},{"key":"10.1016\/j.intimp.2026.116747_bb0255","article-title":"Enhancing precision medicine: bispecific antibody-mediated targeted delivery of lipid nanoparticles for potential cancer therapy","volume":"654","author":"Gu","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2026.116747_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123990","article-title":"Bispecific antibody-mediated targeted delivery of lipid nanoparticles","volume":"654","author":"Zhang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.intimp.2026.116747_bb0265","unstructured":"Al-Dulaymi, A., Yu, X., Zhang, Y., Xu, X., & Xu, X. (2024). Enhancing precision medicine: Bispecific antibody-mediated targeted delivery of lipid nanoparticles for potential cancer therapy. ResearchGate. https:\/\/www.researchgate.net\/publication\/378885029."},{"key":"10.1016\/j.intimp.2026.116747_bb0275","unstructured":"Nature Communications. (2024). A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Nature Communications, 15, Article 44533. https:\/\/www.nature.com\/articles\/s41467-023-44533-z."},{"key":"10.1016\/j.intimp.2026.116747_bb0280","unstructured":"National Center for Biotechnology Information. (n.d.). Bispecific antibody drug conjugates: Making 1+1 > 2. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11119582\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0285","unstructured":"Amgen. (n.d.). Blinatumomab (Blincyto) prescribing information. https:\/\/www.pi.amgen.com\/united_states\/blincyto\/blincyto_pi_hcp_english.pdf."},{"key":"10.1016\/j.intimp.2026.116747_bb0290","article-title":"T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a therapeutic platform","volume":"287","author":"Zhang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.intimp.2026.116747_bb0295","unstructured":"Google Patents. (2022). Long-acting bi-specific T-cell engagers targeting CD3 and CD47 (WO2022105787A1). https:\/\/patents.google.com\/patent\/WO2022105787A1\/en."},{"key":"10.1016\/j.intimp.2026.116747_bb0300","unstructured":"Liu, Z., Li, Y., Li, X., & Yang, J. (2023). Advances in half-life extension strategies for therapeutic antibodies and antibody fragments: focus on bispecific antibody. Pharmaceuticals, 16(11), 1432."},{"issue":"21","key":"10.1016\/j.intimp.2026.116747_bb0305","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2026.116747_bb0310","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibody: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2026.116747_bb0315","unstructured":"Genentech. (2022). Odronextamab (REGN1979) - Product pipeline overview. Retrieved from https:\/\/www.gene.com\/media\/press-releases\/14928\/2022-12-14\/regn1979-clinical-trial-data."},{"issue":"696","key":"10.1016\/j.intimp.2026.116747_bb0320","doi-asserted-by":"crossref","first-page":"eabm1262","DOI":"10.1126\/scitranslmed.abm1262","article-title":"Delivery of PEGylated liposomal doxorubicin by Bispecific antibody improves treatment in models of high-risk childhood leukemia","volume":"15","author":"Moles","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116747_bb0325","unstructured":"Celsion Corporation. (2018). Celsion Corporation announces issuance of new patent for ThermoDox\u00ae. Retrieved from https:\/\/investor.celsion.com\/news-releases\/news-release-details\/celsion-corporation-announces-issuance-new-patent thermodoxr."},{"key":"10.1016\/j.intimp.2026.116747_bb0330","unstructured":"Celsion Corporation. (2017). Celsion announces results of Phase III HEAT study of ThermoDox\u00ae. Retrieved from https:\/\/www.fiercebiotech.com\/biotech\/celsion-announces-results-of-phase-iii-heat-study-of-thermodox%C2%AE-primary-liver-cancer."},{"key":"10.1016\/j.intimp.2026.116747_bb0335","first-page":"1","article-title":"Novel antibody-targeted liposomes for the treatment of solid tumors","volume":"91","author":"Bolkestein","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.116747_bb0340","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/CJI.0b013e318156750c","article-title":"Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class","volume":"30","author":"Brischwein","year":"2007","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.intimp.2026.116747_bb0345","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0350","first-page":"251","article-title":"Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion","volume":"420","author":"Johnson","year":"2018","journal-title":"J. Mol. Biol."},{"issue":"15_suppl","key":"10.1016\/j.intimp.2026.116747_bb0355","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2020.38.15_suppl.3004","article-title":"Antagonistic targeting of PD-1 and LAG-3 with bispecific DART molecule MGD013 in patients with advanced solid tumors: phase I dose-escalation results","volume":"38","author":"Lipson","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.intimp.2026.116747_bb0360","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0365","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0370","first-page":"e185","article-title":"Odronextamab, a CD20\u00d7CD3 bispecific antibody, in relapsed\/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose escalation and expansion study","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.intimp.2026.116747_bb0375","unstructured":"Integral Molecular. (2023). Profusion Antibody Discovery Platform. Retrieved from https:\/\/www.integralmolecular.com\/profusion\/."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0380","first-page":"313","article-title":"Targeting membrane protein interactions with therapeutic antibodies","volume":"40","author":"Krantz","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0385","first-page":"649","article-title":"A phase Ib study of vanucizumab (anti-angiopoietin-2\/vascular endothelial growth factor-A CrossMAb antibody) and atezolizumab in patients with advanced solid tumors","volume":"28","author":"Bendell","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0390","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4161\/mabs.21379","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"4","author":"Klein","year":"2012","journal-title":"mAbs"},{"issue":"27","key":"10.1016\/j.intimp.2026.116747_bb0395","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116747_bb0400","unstructured":"Amgen. (2023). Pipeline overview. Retrieved from https:\/\/www.amgen.com."},{"issue":"12","key":"10.1016\/j.intimp.2026.116747_bb0405","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.intimp.2026.116747_bb0410","first-page":"3944","article-title":"AMG 701, a half-life extended anti-BCMA BiTE\u00ae molecule induces potent T cell-mediated anti-tumor activity in multiple myeloma","volume":"26","author":"Hipp","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116747_bb0415","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12 Supplement","key":"10.1016\/j.intimp.2026.116747_bb0420","first-page":"A149","article-title":"Trispecific T-cell activating construct (TriTAC): a novel protein platform for T-cell immunotherapy","volume":"18","author":"Buelow","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2026.116747_bb0425","unstructured":"Harpoon Therapeutics. (2023). Pipeline Overview. Retrieved from https:\/\/www.harpoontx.com\/pipeline."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.116747_bb0430","first-page":"2585","article-title":"Initial results of HPN328, a DLL3-targeting TriTAC-XR T cell engager, in patients with advanced cancers","volume":"40","author":"Therasse","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116747_bb0435","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.intimp.2026.116747_bb0440","first-page":"196","article-title":"Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM \u00d7 anti-CD3) as a targeted cancer immunotherapy","volume":"42","author":"Seimetz","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2026.116747_bb0445","doi-asserted-by":"crossref","first-page":"30613","DOI":"10.1038\/s41598-024-83627-6","article-title":"A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro","volume":"14","author":"Petersen","year":"2024","journal-title":"Sci. Rep."},{"issue":"6428","key":"10.1016\/j.intimp.2026.116747_bb0450","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116747_bb0455","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0460","first-page":"456","article-title":"Efficient construction of \u03ba\u03bb-bodies by site-specific incorporation of functional antibody domains","volume":"6","author":"Steiner","year":"2014","journal-title":"mAbs"},{"issue":"5","key":"10.1016\/j.intimp.2026.116747_bb0465","first-page":"886","article-title":"The \u03ba\u03bb-body platform: engineering bispecific antibody for dual cytokine blockade","volume":"43","author":"Steiner","year":"2015","journal-title":"Biochem. Soc. Trans."},{"issue":"2 Supplement","key":"10.1016\/j.intimp.2026.116747_bb0470","article-title":"MCLA-145, a human CD137xPD-L1 Biclonics\u00ae bispecific antibody, demonstrates potent immune activation and antitumor activity","volume":"9","author":"Haas","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116747_bb0475","unstructured":"Merus N.V (2023). Technology and pipeline overview. Retrieved from https:\/\/www.merus.nl."},{"key":"10.1016\/j.intimp.2026.116747_bb0480","article-title":"HER2 and HER3 crosstalk in cancer: implications for targeted therapy","volume":"86","author":"Moelans","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0485","first-page":"456","article-title":"Efficient construction of functionalized antibodies: FynomAb platform for multispecific antibody therapeutics","volume":"6","author":"Steiner","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.intimp.2026.116747_bb0490","unstructured":"ClinicalTrials.gov. (2016). Study of COVA322 in patients with moderate to severe psoriasis (NCT02243787). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02243787."},{"key":"10.1016\/j.intimp.2026.116747_bb0495","unstructured":"FierceBiotech. (2016, June 10). J&J pulls plug on Covagen's lead bispecific antibody. Retrieved from https:\/\/www.fiercebiotech.com\/biotech\/j-j-pulls-plug-on-covagen-s-lead-bispecific-antibody."},{"issue":"14","key":"10.1016\/j.intimp.2026.116747_bb0500","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2026.116747_bb0505","unstructured":"Regeneron Pharmaceuticals. (2023). Pipeline overview. Retrieved from https:\/\/www.regeneron.com\/pipeline."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0510","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116747_bb0515","unstructured":"Aptevo Therapeutics. (2022). ADAPTIR bispecific platform technology. Retrieved from https:\/\/aptevo.com\/technology\/adaptir-platform\/."},{"issue":"21","key":"10.1016\/j.intimp.2026.116747_bb0520","first-page":"5477","article-title":"Preclinical characterization of APVO436, a CD123 x CD3 bispecific antibody, for hematologic malignancies","volume":"4","author":"Bhatt","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2026.116747_bb0525","unstructured":"ClinicalTrials.gov. (2022). Study of APVO436 in subjects with AML and MDS (NCT03647800). Retrieved from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03647800."},{"key":"10.1016\/j.intimp.2026.116747_bb0530","unstructured":"Xencor. (2023). XmAb\u00ae bispecific Fc platform. Retrieved from https:\/\/www.xencor.com\/technologies\/xmab-platform\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0535","article-title":"Development and clinical applications of Bispecific antibody using the XmAb platform","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116747_bb0540","unstructured":"Affimed N.V (2023). ROCK\u00ae platform: Redirected Optimized Cell Killing. Retrieved from https:\/\/www.affimed.com\/technology\/rock-platform\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0545","unstructured":"F-star Biotechnology Ltd. (2023). Modular Antibody Technology. Retrieved from https:\/\/www.f-star.com\/technology\/modular-antibody-technology\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0550","unstructured":"Pieris Pharmaceuticals. (2023). Anticalin\u00ae proteins: Engineered targeted therapies. Retrieved from https:\/\/www.pieris.com\/technology\/anticalin-proteins\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0710","unstructured":"Evaxion Biotech: AI-Immunology\u2122 Powered Vaccines. [Internet]. 2025 [cited 2025 May 16]. Available from: https:\/\/evaxion.ai\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0560","unstructured":"AstraZeneca. (2023). MedImmune antibody-drug conjugates and bispecific antibody platforms. Retrieved from https:\/\/www.astrazeneca.com\/our-science\/medimmune.html."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0565","first-page":"867","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"23","author":"Kontermann","year":"2012","journal-title":"Curr. Opin. Biotechnol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0570","first-page":"2245","article-title":"Mass spectrometry-based structural characterization of therapeutic antibodies","volume":"21","author":"Fussl","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0575","first-page":"2571","article-title":"Advanced SPR for bispecific antibody: simultaneous dual antigen binding kinetics and mechanism","volume":"92","author":"Schumacher","year":"2020","journal-title":"Anal. Chem."},{"issue":"19","key":"10.1016\/j.intimp.2026.116747_bb0580","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.1021\/ac901154s","article-title":"Analysis of protein conformation and dynamics by hydrogen\/deuterium exchange MS","volume":"81","author":"Engen","year":"2009","journal-title":"Anal. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0585","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/adt.2011.0380","article-title":"Molecular interaction studies using microscale thermophoresis","volume":"9","author":"Jerabek-Willemsen","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116747_bb0590","first-page":"73","article-title":"Multi-angle light scattering coupled to SEC: a powerful tool for determining molecular weights and sizes of proteins and protein complexes","volume":"10","author":"Garcia","year":"2018","journal-title":"Biophys. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0595","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ab.2008.03.035","article-title":"Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet","volume":"377","author":"Abdiche","year":"2008","journal-title":"Anal. Biochem."},{"issue":"12","key":"10.1016\/j.intimp.2026.116747_bb0600","first-page":"1211","article-title":"Next-generation sequencing for antibody discovery and engineering","volume":"14","author":"Robinson","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"issue":"9","key":"10.1016\/j.intimp.2026.116747_bb0605","first-page":"919","article-title":"Machine-learning-guided directed evolution for protein engineering","volume":"18","author":"Yang","year":"2021","journal-title":"Nat. Methods"},{"issue":"W1","key":"10.1016\/j.intimp.2026.116747_bb0610","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"7873","key":"10.1016\/j.intimp.2026.116747_bb0615","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0620","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/prot.22921","article-title":"Role of conformational sampling in computing mutation-induced changes in protein structure and stability","volume":"79","author":"Kellogg","year":"2011","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.intimp.2026.116747_bb0625","article-title":"Generative models for graph-based protein design","volume":"13","author":"Ingraham","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.patter.2021.100406","article-title":"Antibody structure prediction using interpretable deep learning","volume":"3","author":"Ruffolo","year":"2022","journal-title":"Patterns"},{"key":"10.1016\/j.intimp.2026.116747_bb0635","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molstruc.2014.03.009","article-title":"MicroScale thermophoresis: interaction analysis and beyond","volume":"1077","author":"Jerabek-Willemsen","year":"2014","journal-title":"J. Mol. Struct."},{"issue":"2","key":"10.1016\/j.intimp.2026.116747_bb0640","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jmb.2014.09.026","article-title":"The CamSol method of rational design of protein mutants with enhanced solubility","volume":"427","author":"Sormanni","year":"2015","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0645","article-title":"Causability and explainability of artificial intelligence in medicine","volume":"9","author":"Holzinger","year":"2019","journal-title":"Wiley Interdiscip. Rev.: Data Mining Knowl. Discov."},{"key":"10.1016\/j.intimp.2026.116747_bb0650","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-388403-9.00013-8","article-title":"Multi-scale modeling of tissues using CompuCell3D","volume":"110","author":"Swat","year":"2012","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.intimp.2026.116747_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2018.00031","article-title":"Digital twins in health care: ethical implications of an emerging engineering paradigm","volume":"9","author":"Bruynseels","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.intimp.2026.116747_bb0660","unstructured":"AbSci. (2023). [Company website]. Retrieved from https:\/\/www.absci.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0665","unstructured":"DeepMirror. (2023). AI-accelerated antibody discovery. [Company website]. Retrieved from https:\/\/www.deepmirror.ai\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0670","unstructured":"Valence Discovery. (2023). AI\/ML-enabled therapeutics. [Company website]. Retrieved from https:\/\/www.valencediscovery.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0675","unstructured":"Insilico Medicine. (2023). AI-powered drug discovery. [Company website]. Retrieved from https:\/\/insilico.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0680","unstructured":"Biolojic Design. (2023). Adaptive antibody therapeutics. [Company website]. Retrieved from https:\/\/biolojic.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0685","unstructured":"LabGenius. (2023). Evolutionary drug discovery with AI. [Company website]. Retrieved from https:\/\/www.labgenius.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0690","unstructured":"XtalPi. (2023). Intelligent drug design. [Company website]. Retrieved from https:\/\/www.xtalpi.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0695","unstructured":"Arzeda. (2023). Protein design by design. [Company website]. Retrieved from https:\/\/arzeda.com\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0700","unstructured":"Menten AI. (2023). Quantum and AI for protein design. [Company website]. Retrieved from https:\/\/www.menten.ai\/."},{"key":"10.1016\/j.intimp.2026.116747_bb0705","unstructured":"Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials. [Internet]. 2021 [cited 2025 May 16]. Available from: https:\/\/investors.exscientia.ai\/press-releases\/press-release-details\/2021\/Exscientia-Announces-First-AI-Designed-Immuno-Oncology-Drug-to-Enter-Clinical-Trials\/."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0720","article-title":"The year of the bispecific in oncology and beyond","volume":"19","author":"Marshall","year":"2025","journal-title":"Nature"},{"issue":"212","key":"10.1016\/j.intimp.2026.116747_bb0725","article-title":"Bispecific antibody: unleashing a new era in oncology treatment","volume":"24","author":"Shui","year":"2025","journal-title":"Mol. Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2026.116747_bb0730","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.2025030376","article-title":"Bispecific antibody in action: the reality of engagement","volume":"146","author":"Shadman","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116747_bb0735","unstructured":"Ujjani, C. S. (2026, February 9). B-Cell lymphoma: Bispecific antibody and CAR T-cell therapy updates from ASH 2025. Cancer News. https:\/\/binaytara.org\/cancernews\/article\/dr-chaitra-s-ujjani-on-b-cell-lymphoma-bispecific-antibodies-and-car-t-cell-therapy-updates-from-ash."},{"key":"10.1016\/j.intimp.2026.116747_bb0740","unstructured":"Mahmoudjafari, Z., Adams, B., Martin, T., et al. (2026, January 20). Bispecific antibody efficacy and safety in multiple myeloma: Updates from ASH 2025. AJMC. https:\/\/www.ajmc.com\/view\/bispecific-antibody-efficacy-and-safety-in-multiple-myeloma-updates-from-ash-2025."},{"key":"10.1016\/j.intimp.2026.116747_bb0745","unstructured":"Banerjee, R., & Klumpp, E. A. (2025, December 17). Bispecific antibody in multiple myeloma: ASH 2025 highlights. Hematology Advisor. https:\/\/www.hematologyadvisor.com\/features\/bispecific-antibodies-in-multiple-myeloma-ash-2025\/."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0750","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4062\/biomolther.2024.146","article-title":"Mechanism of action and pharmacokinetics of approved bispecific antibodies","volume":"32","author":"Choi","year":"2024","journal-title":"Biomol. Ther. (Seoul)"},{"issue":"17","key":"10.1016\/j.intimp.2026.116747_bb0755","doi-asserted-by":"crossref","first-page":"12650","DOI":"10.1074\/jbc.M700820200","article-title":"Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin","volume":"282","author":"M\u00fcller","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0760","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"issue":"9","key":"10.1016\/j.intimp.2026.116747_bb0765","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a Trispecific T Cell\u2013Activating Protein Construct Targeting DLL3-Expressing Solid Tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2026.116747_bb0770","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.759337","article-title":"Pharmacokinetic engineering of OX40-blocking anticalin proteins using monomeric plasma half-life extension domains","volume":"12","author":"Siegemund","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2026.116747_bb0775","first-page":"233","article-title":"Anticalin\u00ae proteins as therapeutic agents in human diseases, BioDrugs (Review; discusses formatting flexibility and half-life","volume":"32","author":"Rothe","year":"2018","journal-title":"tuning)"},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0780","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/19420862.2016.1197457","article-title":"The use of CrossMAb technology for the generation of bi- and multispecific antibodies","volume":"8","author":"Klein","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116747_bb0785","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1038\/ncomms7113","article-title":"Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG (\u03ba\u03bb-body)","volume":"6","author":"Fischer","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.116747_bb0790","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2318817","article-title":"Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies","volume":"16","author":"Aertker","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116747_bb0795","unstructured":"Aptevo Therapeutics. ADAPTIR\u2122 bispecific platform overview (antibody-like half-life; reported rodent half-life values). Company\/SEC presentation page."},{"issue":"5","key":"10.1016\/j.intimp.2026.116747_bb0800","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","article-title":"Redirected optimized cell killing (ROCK\u00ae): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity","volume":"11","author":"Ellwanger","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116747_bb0805","unstructured":"Xencor. XmAb\u00ae Technology overview (Fc engineering; half-life tuning via Fc domain variants)."},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0810","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0815","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116747_bb0820","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2018.08.010","article-title":"Building blocks for bispecific and trispecific antibodies","volume":"154","author":"Wu","year":"2019","journal-title":"Methods"},{"issue":"4","key":"10.1016\/j.intimp.2026.116747_bb0825","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"issue":"3","key":"10.1016\/j.intimp.2026.116747_bb0830","first-page":"617","article-title":"Targeting b-cell maturation antigen (BCMA) in multiple myeloma","volume":"32","author":"Cho","year":"2018","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.intimp.2026.116747_bb0835","first-page":"1001","article-title":"Dual targeting strategies to overcome resistance in immune-mediated diseases","volume":"41","author":"Neumann","year":"2020","journal-title":"Trends Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116747_bb0840","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116747_bb0845","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116747_bb0850","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26115319","article-title":"From molecular precision to clinical practice: a comprehensive review of bispecific and trispecific antibodies in hematologic malignancies","volume":"26","author":"Amoozgar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116747_bb0855","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116747_bb0860","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying cytokine release syndrome mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116747_bb0865","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T-cell synapses by bispecific antibody constructs","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2026.116747_bb0870","article-title":"Cytokine release syndrome trends with T-cell engaging bispecifics from licensing applications","volume":"144","author":"Radtke","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116747_bb0875","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR-T and related therapies","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116747_bb0880","first-page":"273","article-title":"Immune effector cell-associated neurotoxicity syndrome (ICANS) and related neurologic toxicities","volume":"139","author":"Dietrich","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116747_bb0885","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for CRS and ICANS","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.intimp.2026.116747_bb0890","author":"Gloucestershire Hospitals NHS Foundation trust"},{"key":"10.1016\/j.intimp.2026.116747_bb0900","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory CRS or ICANS following immune effector therapies","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.intimp.2026.116747_bb0895","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.116747_bb0905","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.intimp.2026.116747_bb0910","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13036-024-00454-z","article-title":"Construction of bispecific antibodies by specific pairing between heavy and light chains using removable SpyCatcher\/SnoopCatcher units","volume":"18","author":"Yoshida","year":"2024","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.intimp.2026.116747_bb0915","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1016\/j.xphs.2021.04.010","article-title":"Characterization and monitoring of a novel light-heavy-light chain mispair in a therapeutic bispecific antibody","volume":"110","author":"Cao","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2026.116747_bb0920","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1063002","article-title":"Generation of bispecific antibodies by structure-guided redesign of IgG constant regions","volume":"13","author":"Iwasaki","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116747_bb0925","doi-asserted-by":"crossref","first-page":"18630","DOI":"10.1038\/s41598-021-97393-2","article-title":"A new approach to produce IgG4-like bispecific antibodies","volume":"11","author":"Zhao","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116747_bb0930","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2479531","article-title":"Design of orthogonal constant-domain interfaces to aid proper heavy\/light chain pairing of bispecific antibodies","volume":"17","author":"Barlow","year":"2025","journal-title":"MAbs"},{"key":"10.1016\/j.intimp.2026.116747_bb0935","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13036-024-00454-z","article-title":"Forced chain-pairing strategies for bispecific antibody assembly","volume":"18","author":"Yoshida","year":"2024","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.intimp.2026.116747_bb0940","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1021\/acsomega.1c06305","article-title":"Analytical characterization of IgG1 CrossMAb antibodies of the knob-into-hole format","volume":"7","author":"Grunert","year":"2022","journal-title":"ACS Omega"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600593X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600593X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:56:46Z","timestamp":1778821006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600593X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":184,"alternative-id":["S156757692600593X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116747","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rise of bispecific antibodies for dual targeting, singular impact: technology and clinical advancements","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116747"}}